Shkreli
‘Pharma bro’ Shkreli heads to jail
September 14, 2017Medical Communications Martin Shkreli, Shkreli, biotech, drugs, pharma, pharmaceutical
Martin Shkreli’s habit of being unable to stay out of the headlines continues, although this time with the repercussion that …
‘He was born this way’, Shkreli case becomes circus
June 29, 2017Medical Communications Martin Shkreli, Shkreli, Turing Pharmaceutical, turing
Martin Shkreli’s Attorney, Benjamin Brafman, defended his client in a bizarre reference to a pop singer, “As Lady Gaga would …
Retrophin announces positive Phase II results, Shkreli claims credit
September 8, 2016Research and Development Phase II, Retrophin, Shkreli, rare kidney disease
Retrophin has announced positive top-line results for trial drug sparsentan in Phase II to treat a rare kidney disorder with …
Clinton announces plan to tackle “unjustified price hikes”
September 5, 2016Sales and Marketing Drug pricing, Shkreli, US, clinton, generic drugs, president, price hikes
US Presidential candidate Hillary Clinton has outlined a wide-ranging set of proposals to tackle what she calls the “unjustified price …
KaloBios announces new affordable pricing model, refuses to engage in “price gouging”
April 12, 2016Manufacturing and Production, Sales and Marketing CEO, Drug pricing, KaloBios, Martin Shkreli, Shkreli, affordable, price gouging, price model, responsible
Price gouging has become synonymous with drug costs in the US, with the infamous Martin Shkreli and troubled Valeant becoming …
Martin Shkreli resigns from Turing
December 21, 2015Sales and Marketing Martin Shkreli, Shkreli, Turing Pharmaceuticals
Following his arrest on securities fraud charges, Martin Shkreli has resigned as chief executive of Turing and been replaced by …
Turing chief exec Martin Shkreli arrested
December 17, 2015Medical Communications, Sales and Marketing Daraprim, FBI, Martin Shkreli, Shkreli, turing
Turing chief executive Martin Shkreli has been arrested on a charge of securities fraud relating to a company he founded, …
Latest content
